Fasting blood glucose (FBG)

Fasting blood glucose (FBG) represents the concentration of glucose in the blood following a period of nutritional deprivation, typically lasting at least eight hours [1][2]. It is a critical physiological parameter used primarily as a diagnostic and monitoring tool for metabolic disorders like type 2 diabetes and prediabetes [1]. While often described as a 'target' for therapy in clinical guidelines, it is a systemic metabolite and clinical endpoint rather than a molecular therapeutic target such as a protein receptor or enzyme [3]. Pharmacological interventions aimed at lowering FBG do so by interacting with specific molecular targets like the insulin receptor, GLP-1 receptors, or glucose transporters [4]. Maintaining FBG within a specific range is vital for preventing the long-term complications of hyperglycemia, including neuropathy, retinopathy, and cardiovascular disease [2][5].

Other names

Fasting blood sugarFasting plasma glucoseFPGFBSSerum glucose

Drugs modulate fasting glucose levels by various secondary mechanisms, including increasing pancreatic insulin secretion, enhancing peripheral insulin sensitivity, inhibiting hepatic gluconeogenesis, or promoting renal glucose excretion via SGLT2 inhibition [2][4].